No Data
Getein Biotech, Inc. (603387.SH): In the third quarter of 2024, the company installed more than 20 sets of Metis 6000 fully automatic biochemical and immune flow lines.
Gelonghui November 12th. Getein Biotech, Inc (603387.SH) stated at the performance online conference that the company's Metis6000 fully automatic biochemical immune pipeline will install more than 20 units in the third quarter of 2024, more than 70 units in the first three quarters, and a total of more than 120 units installed since going public. They are mainly distributed in the inspection department, with a small number in the emergency department and endocrine department. Among them, the installation in tertiary hospitals accounts for more than 30%, while the installation in secondary hospitals accounts for more than 40%. The terminals mainly cover detection projects such as liver function, tumor markers, myocardial, infectious diseases, inflammation, sex hormones, sugar metabolism, gastric function, and bone metabolism.
Basal Egg Organism: Basal Egg Organism: Third Quarter Report 2024
Egg Biosciences: third quarter report 2024
Getein Biotech,Inc (603387.SH) released its performance for the first three quarters, with a net income of 0.202 billion yuan, a 11.69% year-on-year decrease.
Getein Biotech, Inc. (603387.SH) disclosed its third quarter report for 2024, achieving a revenue of 8....
Getein Biotech,Inc (603387.SH): The net income for the first three quarters was 0.202 billion yuan, a year-on-year decrease of 11.69%.
Gelinghui October 30th | Getein Biotech, Inc. (603387.SH) announced its third quarter report for 2024, with the company's revenue for the first three quarters of 0.88 billion yuan, a year-on-year decrease of 12.10%; net income attributable to shareholders of the listed company of 0.202 billion yuan, a year-on-year decrease of 11.69%; basic earnings per share of 0.40 yuan.
Express News | Getein Biotech, Inc: Subsidiary Jingchuan Diagnosis terminates listing.
No Data
No Data